Nuri Karadurmus, Muhammet Ali Kaplan, Mehmet Ali Nahit Sendur, Yuksel Urun, Umut Demirci, Saziye Burcak Karaca, Sabin Goktas Aydin, Musa Baris Aykan, Ahmet Bilici, Ahmet Sezer, Ulku Yilmaz, Huseyin Abali, Perran Fulden Yumuk, Serkan Degirmencioglu, Ahmet Demirkazik, Semra Paydas, Cem Mirili, Hande Turna, Aysegul Kargi, Mustafa Ozdogan, Deniz Can Guven, Mustafa Ozguroglu, Saadettin Kilickap
OBJECTIVE: To evaluate the efficacy and safety of nivolumab in the second-line (2L) or later-line (LL) treatment of patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) in real-life setting in Türkiye. METHODS: This study was designed as a national, multi-center, retrospective study. The study population was evaluated in two groups for the line of nivolumab therapy: those receiving nivolumab in the 2L (Group 2L) and third-line (3L) or LL (Group 3L/LL)...
May 29, 2024: Current Medical Research and Opinion